MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • 2017 International Congress

    Impact of levodopa-induced dyskinesias on Health-related Quality of Life. Results from the French COPARK study.

    S. Perez-Lloret, L. Negre-Pages, P. Damier, A. Delval, P. Derkinderen, A. Destée, W. Meissner, F. Tison, O. Rascol (Buenos Aires, Argentina)

    Objective: To assess the impact of LIDs on HRQoL in this large sample of unselected Parkinson’s Disease (PD) patients and to assess the factors related…
  • 2017 International Congress

    Decision making under uncertainty in medicated and un-medicated Parkinson’s disesase

    J. Corrow, M. Cherkasova, A. Taylor, J. Stoessl, M. McKeown, S. Apple Creswell, J. Barton (Vancouver, BC, Canada)

    Objective: To evaluate decision making under risk in Parkinson’s disease patients, both medicated and un-medicated states probing constituent cognitive operations driving choice.  Background: Prior literature…
  • 2017 International Congress

    ND0612 (levodopa/carbidopa for subcutaneous infusion) achieves stable levodopa plasma levels when administered in low and high doses in patients with PD

    N. Giladi, Y. Caraco, T. Gurevich, R. Djaldetti, L. Adar, T. Rachmilewitz Minei, S. Oren (Tel Aviv, Israel)

    Objective: Characterize the levodopa pharmacokinetic profile derived from continuous subcutaneous (SC) administration of ND0612. Background: Continuous levodopa/carbidopa (LD/CD) infusion is considered the optimal delivery route…
  • 2017 International Congress

    Factors determining the motor outcome of STN DBS in PD patients: Evidence for Dual Actions

    C. Lee, E.J. Choi, S.-C. Park, J.K. Lee (Seoul, Republic of Korea)

    Objective: We investigated factors determining the motor outcome of STN DBS in patients with Parkinson disease (PD). Background: The STN DBS has revolutionized the management…
  • 2017 International Congress

    Association of Single Nucleotide Polymorphism in MAOB and Risk of Levodopa-Induced Dyskinesias in Parkinson’s Disease

    B. Santos-Lobato, M. Capelari, N. Novaretti, Â. Vieira, V. Borges, H. Ferraz, I. Mata, C. Zabetian, V. Tumas (Ribeirão Preto, Brazil)

    Objective: To identify genetic risk factors for developing levodopa-induced dyskinesias (LID) in patients with Parkinson’s disease (PD). Background: LID are common complications in PD, but…
  • 2017 International Congress

    Identification of the optimal carbidopa concentration in subcutaneously administered ND0612

    L. Adar, T. Rachmilewitz Minei, S. Oren (Rehovot, Israel)

    Objective: To identify the concentration of subcutaneous (SC) carbidopa (CD) that provides optimal bioavailability of a concomitant fixed concentration of levodopa (LD) when administered via…
  • 2017 International Congress

    Combined Surgical Therapies for Optimal Management of Advanced Parkinson’s Disease

    L. Kirkpatrick, Y. Torres-Yaghi, A. Keys, N. Starr, T. Kimbason, C. Moussa, F. Amjad, F. Pagan (Washington, DC, USA)

    Objective: We report a case of a patient with advanced PD who began LCIG for refractory motor fluctuations while continuing longstanding STN-DBS. Background: LCIG and…
  • 2017 International Congress

    Specific Bdnf variants are associated with suboptimal response to levodopa but not to other dopaminergic medications or deep brain stimulation in Parkinson’s disease

    C. Sortwell, P. Auinger, J. Goudreau, B. Pickut, B. Berryhill, M. Hacker, D. [email protected], J. Lipton, A. Cole-Strauss, J. Elm, D. Fischer (Grand Rapids, MI, USA)

    Objective: We examined the impact of rs6265 and other brain-derived neurotrophic factor (Bdnf) variants in two subject cohorts: 1) early-stage Parkinson’s disease (PD) subjects from…
  • 2017 International Congress

    Improvement in attention/memory domains in advanced Parkinson’s disease patients treated with levodopa-carbidopa intestinal gel is associated with better quality of life

    D. Standaert, R. Rodriguez, J. Slevin, M. Lobatz, C. Hall, M. Facheris, J. Benesh, S. Dubow (Birmingham, AL, USA)

    Objective: To evaluate the relationship between non-motor symptom (NMS) severity, quality of life (QoL), and activities of daily living (ADL) in advanced Parkinson’s disease (PD)…
  • 2017 International Congress

    Effects of the administration of levodopa on postural control under visual tasks

    C. Bonnet, A. Delval, L. Defebvre (Lille, France)

    Objective: We tested if the administration of levodopa leads the patients with Parkinson’s disease to sway significantly more than the controls, especially under challenging visual…
  • « Previous Page
  • 1
  • …
  • 44
  • 45
  • 46
  • 47
  • 48
  • …
  • 57
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • #25062 (not found)
    • Welcome to the MDS Abstracts Site
    • Effect of marijuana on Essential Tremor: A case report
    • Advanced Search
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley